EHT201

EHT201 is an experimental therapeutic candidate under development by Euhearing Therapeutics for the treatment of congenital monogenic hearing loss. It is part of a pipeline of genetic medicines designed to address hearing impairment caused by specific single-gene mutations. As of early 2024, EHT201 is in the early research and preclinical stages of development. While the specific genetic target and delivery modality (such as an adeno-associated virus vector) have not been publicly disclosed, the program is categorized within the company's portfolio of treatments for congenital deafness, which typically utilizes gene therapy or RNA-based approaches to restore auditory function.